Minerva Neurosciences Inc (NASDAQ:NERV) — Market Cap & Net Worth
Market Cap & Net Worth: Minerva Neurosciences Inc (NERV)
Minerva Neurosciences Inc (NASDAQ:NERV) has a market capitalization of $161.20 Million ($161.20 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #17450 globally and #4126 in its home market, demonstrating a -16.02% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Minerva Neurosciences Inc's stock price $3.46 by its total outstanding shares 46588709 (46.59 Million). Also see NERV current and non-current assets for a full breakdown of the balance sheet.
Minerva Neurosciences Inc Market Cap History: 2015 to 2026
Minerva Neurosciences Inc's market capitalization history from 2015 to 2026. Data shows change from $2.26 Billion to $161.20 Million (-20.48% CAGR). Also see cash flow conversion of Minerva Neurosciences Inc for how efficiently the company converts equity into cash flow.
Index Memberships
Minerva Neurosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.01% | #480 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #1710 of 3165 |
Weight: Minerva Neurosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Minerva Neurosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Minerva Neurosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Minerva Neurosciences Inc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
21.18x
Minerva Neurosciences Inc's market cap is 21.18 times its annual revenue
Latest Price to Earnings (P/E) Ratio
449.33x
Minerva Neurosciences Inc's market cap is 449.33 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2019 | $2.65 Billion | $41.18 Million | -$72.18 Million | 64.36x | N/A |
| 2020 | $872.14 Million | $41.18 Million | $1.94 Million | 21.18x | 449.33x |
Competitor Companies of NERV by Market Capitalization
Companies near Minerva Neurosciences Inc in the global market cap rankings as of September 18, 2026. Review tangible net worth ratio of Minerva Neurosciences Inc to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Minerva Neurosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
Minerva Neurosciences Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Minerva Neurosciences Inc's market cap moved from $2.26 Billion to $ 161.20 Million, with a yearly change of -20.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $161.20 Million | -13.93% |
| 2025 | $187.29 Million | +80.95% |
| 2024 | $103.50 Million | -63.88% |
| 2023 | $286.52 Million | +286.79% |
| 2022 | $74.08 Million | -75.19% |
| 2021 | $298.54 Million | -65.77% |
| 2020 | $872.14 Million | -67.09% |
| 2019 | $2.65 Billion | +5.49% |
| 2018 | $2.51 Billion | +11.40% |
| 2017 | $2.25 Billion | -48.51% |
| 2016 | $4.38 Billion | +93.57% |
| 2015 | $2.26 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of Minerva Neurosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $161.20 Million USD |
| MoneyControl | $161.20 Million USD |
| MarketWatch | $161.20 Million USD |
| marketcap.company | $161.20 Million USD |
| Reuters | $161.20 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Minerva Neurosciences Inc
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in… Read more